DK171531B1 - Isoleret biologisk aktivt humant lymphotoxinderiv at og antistof som neutraliserer den cytolytiske aktivitet af dette, nucleinsyre som koder for lymphotoxinderivatet, replikerbar vektor omfattende nucleinsyren, heterolog celle transformeret med nucleinsyren og fremgangsmåde som omfatter fremstilling af lymphotoxinderivatet. - Google Patents

Isoleret biologisk aktivt humant lymphotoxinderiv at og antistof som neutraliserer den cytolytiske aktivitet af dette, nucleinsyre som koder for lymphotoxinderivatet, replikerbar vektor omfattende nucleinsyren, heterolog celle transformeret med nucleinsyren og fremgangsmåde som omfatter fremstilling af lymphotoxinderivatet. Download PDF

Info

Publication number
DK171531B1
DK171531B1 DK241385A DK241385A DK171531B1 DK 171531 B1 DK171531 B1 DK 171531B1 DK 241385 A DK241385 A DK 241385A DK 241385 A DK241385 A DK 241385A DK 171531 B1 DK171531 B1 DK 171531B1
Authority
DK
Denmark
Prior art keywords
lymphotoxin
nucleic acid
dna
vector
sequence
Prior art date
Application number
DK241385A
Other languages
Danish (da)
English (en)
Other versions
DK241385D0 (da
DK241385A (da
Inventor
Bharat Bhushan Aggarwal
Timothy Schot Bringman
Patrick William Gray
Glenn Evan Nedwin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/616,502 external-priority patent/US4959457A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of DK241385D0 publication Critical patent/DK241385D0/da
Publication of DK241385A publication Critical patent/DK241385A/da
Priority to DK56995A priority Critical patent/DK172382B1/da
Application granted granted Critical
Publication of DK171531B1 publication Critical patent/DK171531B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK241385A 1984-05-31 1985-05-30 Isoleret biologisk aktivt humant lymphotoxinderiv at og antistof som neutraliserer den cytolytiske aktivitet af dette, nucleinsyre som koder for lymphotoxinderivatet, replikerbar vektor omfattende nucleinsyren, heterolog celle transformeret med nucleinsyren og fremgangsmåde som omfatter fremstilling af lymphotoxinderivatet. DK171531B1 (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK56995A DK172382B1 (da) 1984-05-31 1995-05-18 Rekombinante lymphotoxinderivater

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US61650384A 1984-05-31 1984-05-31
US61650284 1984-05-31
US06/616,502 US4959457A (en) 1984-05-31 1984-05-31 Anti-lymphotoxin
US61650384 1984-05-31
US73231285A 1985-05-09 1985-05-09
US73231285 1985-05-09

Publications (3)

Publication Number Publication Date
DK241385D0 DK241385D0 (da) 1985-05-30
DK241385A DK241385A (da) 1985-12-01
DK171531B1 true DK171531B1 (da) 1996-12-23

Family

ID=27417179

Family Applications (1)

Application Number Title Priority Date Filing Date
DK241385A DK171531B1 (da) 1984-05-31 1985-05-30 Isoleret biologisk aktivt humant lymphotoxinderiv at og antistof som neutraliserer den cytolytiske aktivitet af dette, nucleinsyre som koder for lymphotoxinderivatet, replikerbar vektor omfattende nucleinsyren, heterolog celle transformeret med nucleinsyren og fremgangsmåde som omfatter fremstilling af lymphotoxinderivatet.

Country Status (23)

Country Link
EP (2) EP0164965B1 (ja)
JP (3) JP2521703B2 (ja)
AR (1) AR245219A1 (ja)
AT (2) ATE95243T1 (ja)
AU (1) AU599303B2 (ja)
BG (1) BG60256B1 (ja)
CA (1) CA1340641C (ja)
CZ (1) CZ283148B6 (ja)
DE (2) DE3587597T2 (ja)
DK (1) DK171531B1 (ja)
ES (1) ES8802182A1 (ja)
FI (1) FI93025C (ja)
GR (1) GR851317B (ja)
HU (1) HU204085B (ja)
IE (1) IE63487B1 (ja)
IL (1) IL75318A (ja)
NO (1) NO179075C (ja)
NZ (1) NZ212207A (ja)
PL (1) PL155410B1 (ja)
PT (1) PT80573B (ja)
RO (1) RO100383A2 (ja)
SK (1) SK278333B6 (ja)
YU (1) YU47735B (ja)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0041313B1 (en) 1980-04-03 1990-09-12 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing human fibroblast interferon
NZ212207A (en) 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
US5683688A (en) 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
JP2557053B2 (ja) * 1984-12-21 1996-11-27 バイオジェン インコーポレイテッド 腫瘍壊死因子の精製、製造および使用法
JPS62111928A (ja) * 1985-10-15 1987-05-22 Kanegafuchi Chem Ind Co Ltd 新規リンホトキシン
JPS62195285A (ja) * 1986-02-19 1987-08-28 Kanegafuchi Chem Ind Co Ltd リンホトキシン発現ベクタ−及びそれを用いるリンホトキシンの製造方法
AU603768B2 (en) * 1985-07-04 1990-11-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin
US5403725A (en) * 1985-12-24 1995-04-04 Denki Kagaku Kogyo Kabushiki Kaisha Method for production of lymphotoxin (TNFB) in cell line A-C5-8
JP2548204B2 (ja) * 1987-06-27 1996-10-30 電気化学工業株式会社 新生理活性ポリペプチド
EP0230781B1 (en) * 1985-12-24 1992-07-22 Denki Kagaku Kogyo Kabushiki Kaisha Lymphotoxin gene, method for its production, and lymphotoxin
EP0230574A3 (en) * 1986-01-31 1989-03-22 Yale University Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
JPS62181298A (ja) * 1986-02-05 1987-08-08 Kyowa Hakko Kogyo Co Ltd ヒトリンホトキシンポリペプチド誘導体
DE3620656A1 (de) * 1986-06-20 1987-12-23 Basf Ag Polypeptide mit lymphotoxin-aktivitaet oder lymphotoxin-aehnlicher aktivitaet, ihre herstellung und verwendung
JPS63105680A (ja) * 1986-10-22 1988-05-10 Kanegafuchi Chem Ind Co Ltd ヒト・リンホトキシン発現ベクタ−、該発現ベクタ−による形質転換細胞および該細胞を用いるリンホトキシンの製造方法
EP0272894A3 (en) * 1986-12-24 1989-06-14 Takeda Chemical Industries, Ltd. Recombinant human lymphotoxin
US5175268A (en) * 1986-12-24 1992-12-29 Takeda Chemical Industries, Ltd. DNA encoding recombinant human lymphotoxin
FI884798A (fi) * 1987-10-28 1989-04-29 Eisai Co Ltd Rekombinantlymfotoxin.
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
GB2217326B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene encoding human tumour necrosis factor beta.
EP0338497A3 (en) * 1988-04-22 1990-05-16 Takeda Chemical Industries, Ltd. Bispecific hybrid monoclonal antibody
JPH023698A (ja) * 1988-06-20 1990-01-09 Denki Kagaku Kogyo Kk ヒトリンホトキシンに対するモノクローナル抗体及びそれら抗体を産生するハイブリドーマ、並びにそれら抗体を用いたヒトリンホトキシンの精製方法、測定方法及び測定試薬
CA2001756A1 (en) * 1988-10-31 1991-04-30 Seiichi Uesugi New human lymphotoxin n-end deletion mutant
JPH03106821A (ja) * 1989-09-20 1991-05-07 Denki Kagaku Kogyo Kk 抗腫瘍剤
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
WO1996022790A1 (en) * 1995-01-23 1996-08-01 Xenotech Incorporated Composition to ameliorate osteolysis and metastasis
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
WO1999036535A1 (en) 1998-01-15 1999-07-22 Genentech, Inc. Apo-2 ligand
EP2314676A1 (en) * 2002-11-26 2011-04-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1641827A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP1699486A4 (en) * 2003-12-08 2007-07-18 Centocor Inc ANTI-LYMPHOTOXIN HUMAN ALPHA ANTIBODIES, COMPOSITIONS, METHODS AND USES
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
CL2007002926A1 (es) * 2006-10-12 2008-05-16 Genentech Inc Anticuerpo antilinfotoxina alfa (lt-alfa); composicion con el anticuerpo; hibridoma pta-7538; acido nucleico codificante del anticuerpo; vector y celula huesped que comprenden el acido nucleico; metodo para inhibir la proliferacion celular activada p
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CA2666934A1 (en) 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
JP6702883B2 (ja) * 2014-04-25 2020-06-03 ノーレックス インコーポレイテッド 向神経活性ペプチドの安定な組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8105035A1 (es) * 1978-12-22 1981-05-16 Biogen Nv Un metodo para producir al menos un polipeptido que muestra antigenicidad de hbv
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
ZA834976B (en) * 1982-07-30 1984-08-29 Genentech Inc Human lymphotoxin
FI82266C (fi) 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
EP0135797A3 (de) * 1983-08-30 1987-11-11 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung von Lymphotoxin und von Lymphotoxin-mRNA
DE3331108A1 (de) * 1983-08-30 1985-05-02 Boehringer Ingelheim International GmbH, 6507 Ingelheim Verfahren zur herstellung von lymphotoxin und von lymphotoxin-mrna
NZ212207A (en) 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin

Also Published As

Publication number Publication date
NO852173L (no) 1985-12-02
PL155410B1 (en) 1991-11-29
ES543695A0 (es) 1988-04-16
DE3587597D1 (de) 1993-11-04
EP0164965A3 (en) 1988-04-06
FI852143A0 (fi) 1985-05-29
SK393085A3 (en) 1996-11-06
RO100383A2 (ro) 1991-10-17
ATE95243T1 (de) 1993-10-15
PT80573B (pt) 1987-08-19
DK241385D0 (da) 1985-05-30
JPH07250692A (ja) 1995-10-03
AU599303B2 (en) 1990-07-19
DE3588225T2 (de) 2001-04-05
FI852143L (fi) 1985-12-01
BG60256B2 (bg) 1994-03-24
IE851321L (en) 1985-11-30
JPS6156197A (ja) 1986-03-20
DE3588225D1 (de) 2000-09-14
ES8802182A1 (es) 1988-04-16
NZ212207A (en) 1991-07-26
NO179075B (no) 1996-04-22
FI93025C (fi) 1995-02-10
IL75318A (en) 1994-08-26
IE930589L (en) 1985-11-30
AR245219A1 (es) 1993-12-30
RO100383B1 (ro) 1991-03-01
GR851317B (ja) 1985-11-25
EP0509553B1 (en) 2000-08-09
JPH07291995A (ja) 1995-11-07
NO179075C (no) 1996-07-31
EP0509553A1 (en) 1992-10-21
ATE195323T1 (de) 2000-08-15
YU47735B (sh) 1996-01-08
HU204085B (en) 1991-11-28
YU91985A (en) 1988-12-31
PL253739A1 (en) 1986-03-11
HUT37814A (en) 1986-02-28
IE63487B1 (en) 1995-05-03
CZ393085A3 (en) 1997-07-16
CA1340641C (en) 1999-07-13
DK241385A (da) 1985-12-01
JP2804237B2 (ja) 1998-09-24
SK278333B6 (en) 1996-11-06
EP0164965B1 (en) 1993-09-29
DE3587597T2 (de) 1994-06-01
CZ283148B6 (cs) 1998-01-14
AU4320385A (en) 1985-12-05
BG60256B1 (bg) 1994-03-24
PT80573A (en) 1985-06-01
IL75318A0 (en) 1985-09-29
FI93025B (fi) 1994-10-31
JP2521703B2 (ja) 1996-08-07
EP0164965A2 (en) 1985-12-18

Similar Documents

Publication Publication Date Title
DK171531B1 (da) Isoleret biologisk aktivt humant lymphotoxinderiv at og antistof som neutraliserer den cytolytiske aktivitet af dette, nucleinsyre som koder for lymphotoxinderivatet, replikerbar vektor omfattende nucleinsyren, heterolog celle transformeret med nucleinsyren og fremgangsmåde som omfatter fremstilling af lymphotoxinderivatet.
JP2614989B2 (ja) 腫瘍壊死因子含有組成物
US4650674A (en) Synergistic cytotoxic composition
US5639455A (en) Immunosuppressant
US5475087A (en) Antagonists of human granulocyte-macrophage colony stimulating factor derived from the carboxyl terminus
NO893452L (no) Rekombinant naturlig dreper-celleaktivator.
US5683688A (en) Unglycosylated recombinant human lymphotoxin polypeptides and compositions
US4959457A (en) Anti-lymphotoxin
DK172382B1 (da) Rekombinante lymphotoxinderivater
JP2675294B2 (ja) ヒト腫瘍壊死因子
NZ226980A (en) Lymphotoxin-neutralising antibody and its use in separating out lymphotoxin from a composition
IL104297A (en) Lymphotoxin Nucleic acid encoding vectors containing the nucleic acid and cells converted by them Methods for obtaining lymphotoxin
US6686455B1 (en) Tumor necrosis factor

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired